Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Analyzing AML: novel therapies in review

Farhad Ravandi • 1 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Gilteritinib Glasdegib Venetoclax

Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, shares key highlights, including trials, future outlooks, and progressions in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Farhad Ravandi

The combination of decitabine, venetoclax, and gilteritinib for treating AML in older adults 1:49
The combination of decitabine, venetoclax, and gilteritinib for treating AML in older adults
Farhad Ravandi • 5 Dec 2025
The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial 1:25
The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial
Farhad Ravandi • 5 Dec 2025
The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML 2:03
The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML
Farhad Ravandi • 11 Jun 2025
Treating older or unfit patients with AML: the current standard and future directions 4:07
Treating older or unfit patients with AML: the current standard and future directions
Farhad Ravandi • 11 Jun 2025

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals